You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》建銀國際降信達生物(01801.HK)目標至53.4元 基本面可靠為行業首選
阿思達克 12-18 10:54
建銀國際發表報告,預料信達生物(01801.HK)下半年產品總收入按年升39%,意味著第四季按年增長32%,主要是公司的醫保重點藥品有望免受今年第三季行業藥品採購延遲的影響。該行指,公司正逐步恢復藥品會議研討會、促銷活動和相關行銷活動,並令集團全年調整後淨虧損預測下調至9.63億元人民幣,明年調整後淨虧損預測下調至4.32億元人民幣,並料2025年調整後純利預測料下調至1,300萬元人民幣。 該行將其目標價由57元下調至53.4元,維持其評級為「跑贏大市」,並形容其基本面可靠,視其為行業首選。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account